Subacute sclerosing panencephalitis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
No edit summary
Line 1: Line 1:
'''For patient information, click [[Subacute sclerosing panencephalitis (patient information)|here]]'''
{{Infobox_Disease |
{{Infobox_Disease |
   Name          = Subacute sclerosing panencephalitis |
   Name          = Subacute sclerosing panencephalitis |
Line 16: Line 17:
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}
{{Editor Help}}


{{SK}} SSPE, Dawson Disease, Dawson encephalitis and measles encephalitis
{{SK}} SSPE, Dawson Disease, Dawson encephalitis and measles encephalitis
Line 51: Line 50:
SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself.
SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself.


==External links==
* {{MerckHome|23|273|l}}
* {{cite journal |author=Bonthius D, Stanek N, Grose C |title=Subacute sclerosing panencephalitis, a measles complication, in an internationally adopted child |journal=Emerg Infect Dis |volume=6 |issue=4 |pages=377-81 |year=2000  |pmid=10905971 |url=http://www.cdc.gov/ncidod/eid/vol6no4/bonthius.htm}}
* {{NINDS|subacute_panencephalitis}}
* {{WhoNamedIt|synd|1889}}
{{Viral diseases}}
{{Viral diseases}}
{{Symptoms and signs}}
{{Symptoms and signs}}
Line 73: Line 67:
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Overview complete]]

Revision as of 15:26, 6 August 2011

For patient information, click here

Subacute sclerosing panencephalitis
Brain: Subacute Sclerosing Panencephalitis: Micro high mag H&E inflammatory reaction (well depicted).
Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology
ICD-10 A81.1
ICD-9 046.2
OMIM 260470
DiseasesDB 12597
MedlinePlus 001419
MeSH C02.182.500.300.600

WikiDoc Resources for Subacute sclerosing panencephalitis

Articles

Most recent articles on Subacute sclerosing panencephalitis

Most cited articles on Subacute sclerosing panencephalitis

Review articles on Subacute sclerosing panencephalitis

Articles on Subacute sclerosing panencephalitis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Subacute sclerosing panencephalitis

Images of Subacute sclerosing panencephalitis

Photos of Subacute sclerosing panencephalitis

Podcasts & MP3s on Subacute sclerosing panencephalitis

Videos on Subacute sclerosing panencephalitis

Evidence Based Medicine

Cochrane Collaboration on Subacute sclerosing panencephalitis

Bandolier on Subacute sclerosing panencephalitis

TRIP on Subacute sclerosing panencephalitis

Clinical Trials

Ongoing Trials on Subacute sclerosing panencephalitis at Clinical Trials.gov

Trial results on Subacute sclerosing panencephalitis

Clinical Trials on Subacute sclerosing panencephalitis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Subacute sclerosing panencephalitis

NICE Guidance on Subacute sclerosing panencephalitis

NHS PRODIGY Guidance

FDA on Subacute sclerosing panencephalitis

CDC on Subacute sclerosing panencephalitis

Books

Books on Subacute sclerosing panencephalitis

News

Subacute sclerosing panencephalitis in the news

Be alerted to news on Subacute sclerosing panencephalitis

News trends on Subacute sclerosing panencephalitis

Commentary

Blogs on Subacute sclerosing panencephalitis

Definitions

Definitions of Subacute sclerosing panencephalitis

Patient Resources / Community

Patient resources on Subacute sclerosing panencephalitis

Discussion groups on Subacute sclerosing panencephalitis

Patient Handouts on Subacute sclerosing panencephalitis

Directions to Hospitals Treating Subacute sclerosing panencephalitis

Risk calculators and risk factors for Subacute sclerosing panencephalitis

Healthcare Provider Resources

Symptoms of Subacute sclerosing panencephalitis

Causes & Risk Factors for Subacute sclerosing panencephalitis

Diagnostic studies for Subacute sclerosing panencephalitis

Treatment of Subacute sclerosing panencephalitis

Continuing Medical Education (CME)

CME Programs on Subacute sclerosing panencephalitis

International

Subacute sclerosing panencephalitis en Espanol

Subacute sclerosing panencephalitis en Francais

Business

Subacute sclerosing panencephalitis in the Marketplace

Patents on Subacute sclerosing panencephalitis

Experimental / Informatics

List of terms related to Subacute sclerosing panencephalitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: SSPE, Dawson Disease, Dawson encephalitis and measles encephalitis

Overview

Subacute sclerosing panencephalitis (SSPE) is a rare chronic, progressive encephalitis that affects primarily children and young adults, caused by defective measles virus (which can be a result of a mutation of the virus itself). 1 in 100,000 people infected with measles are at risk. SSPE is 'incurable' but the condition can be managed by medication if treatment is started at an early stage. Much of the work on SSPE has been completed by the NINDS.

Symptoms

Characterized by a history of primary measles infection before the age of 2 years, followed by several asymptomatic years (6–15 on average), and then gradual, progressive psychoneurological deterioration, consisting of personality change, seizures, myoclonus, ataxia, photosensitivity, ocular abnormalities, spasticity, and coma.

Progression

The progression of symptoms begins with stage 1 — in this stage the behaviour of person become more abnormal and erratic, the person can be irritable and personality alterations can occur. This is often accompanied by memory loss and mental deterioration characterised by intellectual difficulty. As the nervous system begins to lose control of movement, the person develops myoclonic spasms/jerks (these being involuntary motions and spasms in extremities). The myoclonic spasm is a key warning sign of SSPE as these spasms are only normally seen as the body drifts off to sleep — breathing rate decreases, heart rate slows and body temperature lowers causing the brain to think the body is dying and so a myoclonic spasm ensues to try and rouse the body — and so if myclonic spasms are seen when the person isn't tired or during the day then this is indicative of a potentially serious problem (such as SSPE). As the disease progresses towards stage 2, the intensity of the spasms and the mental deterioration increases. The spasms can grow to such an extent that loss of the ability to walk can be a common sign. Also, the person will suffer speech impairment and increasingly deteriorated comprehension coupled with dysphagia. At this point the infection is at stage 2. The final, advanced stages of SSPE include the steady decline in body function with increased intensity of the stage 2 symptoms/signs and also blindness. At the end of the final stages the person is likely to be mute and/or comatose.

Diagnosis

Characteristic periodic activity is seen on EEG (this activity showing widespread cortical dysfunction); pathologically, the white matter of both the hemispheres and brainstem are affected, as well as the cerebral cortex, and eosinophilic inclusion bodies are present in the cytoplasm nuclei of neurons and glial cells. Diagnosis of SSPE is often difficult due to a normal CSF profile — noted changes in the CSF profile only include a marked elevation in CSF immunoglobulin.

Prognosis

Death usually occurs within 3 years. If the diagnosis is made during stage 1 of the SSPE infection then it is possible to cure the disease. However, once SSPE progresses to stage 2 then it is universally fatal in all occurrences. The standard rate of decline spans anywhere between 1–3 years after the onset of the infection. The progression of each stage is unique to the sufferer and cannot be predicted although the pattern or symptoms/signs can be. Although the prognosis is bleak for SSPE past stage 1, it should be noted that there is a 5% remission rate — this may be either a full remission or an improvement in condition giving a longer progression period or at least a longer period with the less severe symptoms. Regardless of the stage that the infection is at, treatment with isonine pranobex combined with interferon can give up to a 50% remission/improvement rate.

Treatment

Should the viral progression be diagnosed during stage 1 (even during late stage 1 when stage 2 symptoms start to manifest themselves) then treatment to combat the infection can be administered successfully — there is no cure for SSPE but if it is caught early enough then the sufferer can respond to the treatment and prevent symptom recurrence by taking the medication for the rest of their life. The treatment for the SSPE infection is the immunomodulator interferon and specific antiviral medication — ribavirin and inosine pranobex are specifically used to greater effect than antivirals such as Amantadine. For those who have progressed to stage 2 or beyond then the disease is incurable. For patients in the terminal phase of the disease there is a palliative care and treatment scheme — this involves anticonvulsant therapy (to help with the body's progressive loss of control of the nervous system causing gradually more intensive spasms/convulsions) alongside supportive measures to help maintain vital functioning. It is fairly standard as the infection's spread and symptoms intensify that feeding tubes need to be inserted to keep a nutritional balance. As the disease progresses to its most advanced phase, the patient will need constant nursing as normal bodily function declines to the complete collapse of the nervous system. Combinations of treatment for SSPE include:

  • Oral inosine pranobex (oral isoprinosine) combined with intrathecal (injection through a lumbar puncture into the spinal fluid) or intraventricular interferon alpha.
  • Oral inosine pranobex (oral isoprinosine) combined with interferon beta.
  • Intrathecal interferon alpha combined with intravenous ribavirin.

Global patterns of infection

SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself.

Template:Viral diseases

Template:Skin and subcutaneous tissue symptoms and signs Template:Nervous and musculoskeletal system symptoms and signs Template:Urinary system symptoms and signs Template:Cognition, perception, emotional state and behaviour symptoms and signs Template:Speech and voice symptoms and signs Template:General symptoms and signs

Template:SIB fi:Subakuutti sklerosoiva panenkefaliitti

Template:WikiDoc Sources